Dan MacLeod

Dan MacLeod

Company: Precision Biosciences

Job title: Head of Cell Therapy


Dr. MacLeod is currently Senior Director of the Cell Therapy Discovery Team at Precision BioSciences. His team is responsible for cell therapy discovery research and preclinical development efforts using Precision’s ARCUS gene-editing technology to engineer human T cells for cancer therapy. Dr. MacLeod was the lead author on a manuscript describing Precision’s process for engineering off-the-shelf allogeneic CAR T cells published in Molecular Therapy and is co-inventor on several granted and pending patents related to Precision’s off-the-shelf CAR T technology. Precision’s first cell therapy product, PBCAR0191, a gene-edited allogeneic CAR T cell candidate targeting CD19, developed in collaboration with Servier, is currently in clinical trials.

Prior to joining Precision, Dr. MacLeod was an Investigator at GlaxoSmithKline working on immunomodulatory drug discovery programs. He performed his postdoctoral work at the International AIDS Vaccine Initiative Neutralizing Antibody Center at the Scripps Research Institute, and at the University of California, San Diego. Dr. MacLeod received a B.A. from Northwestern University with a double major in Biochemistry and Psychology, and a Ph.D. in Molecular Pathology and Biomedical Sciences from the University of California, San Diego.


© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.